Heron Therapeutics vs Zevra Therapeutics
Heron Therapeutics is the larger business, with $155m of revenue in fiscal 2025 against $106m for Zevra Therapeutics (1.5 times as much). Zevra Therapeutics grew faster (350.9% against 7.4%). Zevra Therapeutics kept more of each dollar of sales as profit: a net margin of 78.2% against -13.0%. Zevra Therapeutics carries less debt relative to equity (41.1% against 228.4%).
| Latest fiscal year | Heron TherapeuticsHRTX, 2025 | Zevra TherapeuticsZVRA, 2025 |
|---|---|---|
| Revenue | $155m | $106m |
| Revenue growth | 7.4% | 350.9% |
| Net income | −$20.2m | $83.2m |
| Operating margin | -1.6% | -59.1% |
| Net margin | -13.0% | 78.2% |
| Return on equity | — | 85.7% |
| Free cash flow | −$27.9m | −$2.4m |
| Cash | $28.6m | $62.4m |
| Total debt | $32.7m | $63.6m |
| Debt to equity | 228.4% | 41.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 128 | 61 |
| Market value | $52.7m | $604m |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 13 sales |